JP6831334B2 - 複数エピトープ構築物 - Google Patents

複数エピトープ構築物 Download PDF

Info

Publication number
JP6831334B2
JP6831334B2 JP2017557501A JP2017557501A JP6831334B2 JP 6831334 B2 JP6831334 B2 JP 6831334B2 JP 2017557501 A JP2017557501 A JP 2017557501A JP 2017557501 A JP2017557501 A JP 2017557501A JP 6831334 B2 JP6831334 B2 JP 6831334B2
Authority
JP
Japan
Prior art keywords
seq
epitope
amino acid
atherosclerosis
construct according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017557501A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018505697A5 (https=
JP2018505697A (ja
Inventor
カッカ—，ビジェイ
カッカ―，ビジェイ
ルー，シンジェ
Original Assignee
スロムボーシス リサーチ インスティチュート
スロムボーシス リサーチ インスティチュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1501354.3A external-priority patent/GB201501354D0/en
Priority claimed from GBGB1510195.9A external-priority patent/GB201510195D0/en
Application filed by スロムボーシス リサーチ インスティチュート, スロムボーシス リサーチ インスティチュート filed Critical スロムボーシス リサーチ インスティチュート
Publication of JP2018505697A publication Critical patent/JP2018505697A/ja
Publication of JP2018505697A5 publication Critical patent/JP2018505697A5/ja
Application granted granted Critical
Publication of JP6831334B2 publication Critical patent/JP6831334B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0012—Lipids; Lipoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/118—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2017557501A 2015-01-27 2016-01-25 複数エピトープ構築物 Active JP6831334B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1501354.3 2015-01-27
GBGB1501354.3A GB201501354D0 (en) 2015-01-27 2015-01-27 Multi-epitopic construct
GBGB1510195.9A GB201510195D0 (en) 2015-06-11 2015-06-11 Multi-epitopic construct
GB1510195.9 2015-06-11
PCT/GB2016/050150 WO2016120596A1 (en) 2015-01-27 2016-01-25 Multi-epitopic construct

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020170199A Division JP7204226B2 (ja) 2015-01-27 2020-10-08 複数エピトープ構築物

Publications (3)

Publication Number Publication Date
JP2018505697A JP2018505697A (ja) 2018-03-01
JP2018505697A5 JP2018505697A5 (https=) 2019-03-07
JP6831334B2 true JP6831334B2 (ja) 2021-02-17

Family

ID=55237682

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017557501A Active JP6831334B2 (ja) 2015-01-27 2016-01-25 複数エピトープ構築物
JP2020170199A Active JP7204226B2 (ja) 2015-01-27 2020-10-08 複数エピトープ構築物
JP2022204742A Active JP7662203B2 (ja) 2015-01-27 2022-12-21 複数エピトープ構築物
JP2025053425A Pending JP2025094254A (ja) 2015-01-27 2025-03-27 複数エピトープ構築物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020170199A Active JP7204226B2 (ja) 2015-01-27 2020-10-08 複数エピトープ構築物
JP2022204742A Active JP7662203B2 (ja) 2015-01-27 2022-12-21 複数エピトープ構築物
JP2025053425A Pending JP2025094254A (ja) 2015-01-27 2025-03-27 複数エピトープ構築物

Country Status (5)

Country Link
US (2) US11332515B2 (https=)
EP (1) EP3250584B1 (https=)
JP (4) JP6831334B2 (https=)
GB (1) GB2539743A (https=)
WO (1) WO2016120596A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6831334B2 (ja) 2015-01-27 2021-02-17 スロムボーシス リサーチ インスティチュート 複数エピトープ構築物
USD807376S1 (en) 2015-06-14 2018-01-09 Google Inc. Display screen with animated graphical user interface for smart home automation system having a multifunction status
WO2022043686A1 (en) * 2020-08-25 2022-03-03 Thrombosis Research Institute Vaccine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0002625D0 (en) 2000-02-05 2000-03-29 Trigen Ltd Dendroaspin molecules
WO2001094411A1 (en) * 2000-06-05 2001-12-13 The Regents Of The University Of California Peptides modulating protease activated receptors and methods of using same
EP2281007B1 (en) 2008-04-10 2014-07-09 Thrombosis Research Institute Anti-atheroma vaccine
GB201206761D0 (en) * 2012-04-17 2012-05-30 Thrombosis Res Inst Anti-atherogenic peptides
JP6831334B2 (ja) 2015-01-27 2021-02-17 スロムボーシス リサーチ インスティチュート 複数エピトープ構築物

Also Published As

Publication number Publication date
US20180273608A1 (en) 2018-09-27
US11332515B2 (en) 2022-05-17
CA2974884A1 (en) 2016-08-04
WO2016120596A1 (en) 2016-08-04
GB2539743A8 (en) 2017-01-11
JP7662203B2 (ja) 2025-04-15
US20220195013A1 (en) 2022-06-23
JP2021019614A (ja) 2021-02-18
JP2018505697A (ja) 2018-03-01
GB2539743A (en) 2016-12-28
GB201601286D0 (en) 2016-03-09
EP3250584A1 (en) 2017-12-06
JP7204226B2 (ja) 2023-01-16
JP2023030096A (ja) 2023-03-07
WO2016120596A8 (en) 2018-01-04
EP3250584B1 (en) 2021-05-12
JP2025094254A (ja) 2025-06-24

Similar Documents

Publication Publication Date Title
JP7662203B2 (ja) 複数エピトープ構築物
US8703146B2 (en) Toll-like receptor 5 ligands and methods of use
US20110262449A1 (en) Method for the treatment of gout or pseudogout
JP6858305B2 (ja) 関節リウマチを予防及び治療するための薬物の製造における選択性ｔｎｆｒ１拮抗ペプチドの使用
JP2015166401A (ja) 抗ＩＬ−１α抗体による癌の処置方法
KR20120004994A (ko) 치료적 이용 방법
KR20180123064A (ko) 질환의 요인이 되는 생체내 단백질을 표적으로 하는 컨쥬게이트 백신
US9555086B2 (en) Compositions and methods for inducing an immune response
AU2009226077A1 (en) Heat shock protein gp96 vaccination and methods of using same
US20210106652A1 (en) Immunogenic Compounds For Treatment Of Fibrosis, Autoimmune Diseases And Inflammation
KR20200121825A (ko) 포도상구균 항원을 포함하는 면역원성 조성물
Oscherwitz et al. Low-dose intraperitoneal Freund's adjuvant: Toxicity and immunogenicity in mice using an immunogen targeting amyloid-β peptide
Hainline et al. Active immunotherapy for C5a-mediated inflammation using adjuvant-free self-assembled peptide nanofibers
CN101835483A (zh) 动脉粥样硬化的治疗
JP6247696B2 (ja) ペプチド
JP2005528373A (ja) 免疫プロトコルにＦｌｔ３リガンドを用いる方法
JP7585480B2 (ja) Ｐｄ－ｌ１の細胞外ドメインを含むキメラ抗原
Odales et al. Antitumor efficacy of MUC1-derived variable epitope library treatments in a mouse model of breast cancer
CA2974884C (en) Multi-epitopic construct
JP2018521016A (ja) ＩＬ−２３−ｐ１９ワクチン
WO2013156771A1 (en) Anti-atherogenic peptides
JP2009506986A (ja) ペプチジルジアシルグリセリド
JP6488376B2 (ja) 免疫原性を低減するかまたは予防するためのヒト化コブラ毒因子を含む医薬組成物、薬剤および組み合わせ医薬
AU2017227104A1 (en) Human myosin peptides
EP1973943A1 (en) New method for the treatment of gout or pseudogout

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190124

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20191024

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200226

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201008

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20201008

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20201020

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20201201

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20201208

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210119

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210128

R150 Certificate of patent or registration of utility model

Ref document number: 6831334

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250